Services

  1. NDTMS: community combined review forms

    Combined Review Forms (CRF) for community treatment services to use for Core Dataset P (CDS-P), from April 2020 onwards.

  2. NDTMS: secure setting outcomes forms

    Outcome monitoring forms for use by secure setting from April 2020 for core dataset P.

See more services in this topic

Guidance and regulation

  1. Controlled drugs list
  2. Home Office approved testing kits: annex A
  3. Drug misuse and dependence: UK guidelines on clinical management
  4. COVID-19: guidance for commissioners and providers of services for people who use drugs or alcohol
  5. Precursor chemical licensing
See more guidance and regulation in this topic

News and communications

  1. ACMD public evidence gathering: request for written evidence
  2. Circular 001/2020: Epidyolex scheduling, (SI) 2020 No. 559
  3. ACMD advice on administration rights for therapeutic radiographer independent prescribers
  4. Call for evidence: barriers to research with controlled drugs
See more news and communications in this topic

Research and statistics

  1. Novel benzodiazepines: prevalence and harms in the UK
  2. Substance misuse treatment in secure settings: 2018 to 2019
  3. Shooting Up: infections among people who inject drugs in the UK
  4. Substance misuse treatment for young people: statistics 2018 to 2019
  5. Substance misuse treatment for adults: statistics 2018 to 2019
See more research and statistics in this topic

Policy papers and consultations

  1. Independent review of drugs: call for evidence, part 2
  2. NDTMS annual reports and methodology: proposed changes
  3. ACMD ageing cohort of drug users report: government response
  4. Drug related harms in homeless populations: government response
  5. Drugs policy and medicinal cannabis report: government response
See more policy papers and consultations in this topic

Transparency and freedom of information releases

  1. Standard Operating Procedure for using evidence in ACMD reports
  2. Commissioning impact on drug treatment
  3. Drug strategy 2016: development review
  4. Psychoactive Substances Bill: evaluation review
  5. Methiopropamine: a review of the evidence of use and harm
See more transparency and freedom of information releases in this topic